Literature DB >> 27669439

The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer.

P Chandrasinghe1, J Stebbing2, J Warusavitarne1.   

Abstract

In this issue of the Journal, Schmid et al identify Spondin 2 (SPON2) as a prominent downstream signaling target of metastasis-associated in colon cancer 1 (MACC1) in colorectal cancer (CRC). It is shown that SPON2 mediates MACC1-induced CRC cell proliferation, invasion and metastasis in vitro and in vivo, while its high expression correlates with adverse disease free survival in clinical samples. Therefore, not only does this study shed further light into the complexity of colorectal carcinogenesis, but it also puts forward a potential novel prognostic biomarker to predict high-risk tumors before they metastasize. The MACC1/SPON2 axis may also have utility beyond an indicator of tumor aggressiveness and lends itself as a promising therapeutic target for colorectal and potentially other solid tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27669439     DOI: 10.1038/onc.2016.322

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect.

Authors:  L Lin; H Huang; W Liao; H Ma; J Liu; L Wang; N Huang; Y Liao; W Liao
Journal:  Oncogene       Date:  2014-07-21       Impact factor: 9.867

Review 2.  Personalised cancer medicine.

Authors:  Sarah E Jackson; John D Chester
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

3.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

4.  MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.

Authors:  Ulrike Stein; Wolfgang Walther; Franziska Arlt; Holger Schwabe; Janice Smith; Iduna Fichtner; Walter Birchmeier; Peter M Schlag
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

5.  Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.

Authors:  Sanne de Haas; Paul Delmar; Aruna T Bansal; Matthieu Moisse; David W Miles; Natasha Leighl; Bernard Escudier; Eric Van Cutsem; Peter Carmeliet; Stefan J Scherer; Celine Pallaud; Diether Lambrechts
Journal:  Angiogenesis       Date:  2014-07-11       Impact factor: 9.596

6.  5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.

Authors:  Janindra Warusavitarne; Palaniappan Ramanathan; Anthony Kaufman; Bruce G Robinson; Margaret Schnitzler
Journal:  Int J Colorectal Dis       Date:  2006-03-24       Impact factor: 2.571

7.  Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

Authors:  Shanwu Gao; Chabane Tibiche; Jinfeng Zou; Naif Zaman; Mark Trifiro; Maureen O'Connor-McCourt; Edwin Wang
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

8.  MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer.

Authors:  Yu Zhang; Zhongqiu Wang; Min Chen; Liang Peng; Xinying Wang; Qunying Ma; Fengli Ma; Bo Jiang
Journal:  Mol Cancer       Date:  2012-04-25       Impact factor: 27.401

9.  High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.

Authors:  Katharina Ilm; Wolfgang Kemmner; Marc Osterland; Susen Burock; Gudrun Koch; Pia Herrmann; Peter M Schlag; Ulrike Stein
Journal:  Mol Cancer       Date:  2015-02-14       Impact factor: 27.401

10.  Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients.

Authors:  Qian Zhang; Xiao-Qing Wang; Jie Wang; Shu-Jian Cui; Xiao-Min Lou; Bing Yan; Jie Qiao; Ying-Hua Jiang; Li-Jun Zhang; Peng-Yuan Yang; Feng Liu
Journal:  Oncotarget       Date:  2015-06-20
View more
  5 in total

1.  Spondin2 is a new prognostic biomarker for lung adenocarcinoma.

Authors:  Xiaopeng Yuan; Tingting Bian; Jian Liu; Honggang Ke; Jia Feng; Qing Zhang; Li Qian; Xiaoli Li; Yifei Liu; Jianguo Zhang
Journal:  Oncotarget       Date:  2017-07-26

2.  Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma.

Authors:  Ying Feng; Yilin Hu; Qinsheng Mao; Yibing Guo; Yifei Liu; Wanjiang Xue; Shuqun Cheng
Journal:  J Int Med Res       Date:  2018-10-14       Impact factor: 1.671

3.  Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice.

Authors:  Xiao-Shen Cheng; Ya-Ni Huo; Yan-Yun Fan; Chuan-Xing Xiao; Xiao-Mei Ouyang; Lai-Ying Liang; Ying Lin; Jian-Feng Wu; Jian-Lin Ren; Bayasi Guleng
Journal:  J Cell Mol Med       Date:  2020-07-02       Impact factor: 5.310

4.  Overexpression of Spondin-2 Is Associated with Recurrence-Free Survival in Patients with Localized Clear Cell Renal Cell Carcinoma.

Authors:  Hui-Min Ma; Meng Yu; Cong Wu; Hou-Bao Huang; Ya-Wei Li; Peng Zhang; Jian-Jun Huang; Long Cheng; Gang Feng; Guo-Rong Li
Journal:  Dis Markers       Date:  2020-09-03       Impact factor: 3.434

5.  Association of MACC1 expression with lymphatic metastasis in colorectal cancer: A nested case-control study.

Authors:  Zheying Zhang; Huijie Jia; Yuhang Wang; Baoshun Du; Jiateng Zhong
Journal:  PLoS One       Date:  2021-08-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.